Menu
Home
TMU
FAQ
Sitemap
正體中文
News
Announcements
Events
Business
FAQ
FAQ: IRB
FAQ: Clinical Trial
FAQ: Biobank
Charges
Public Area
About OHR
OHR Overview
Dean
OHR Members
Department
JIRB Administration Section
Data Safety Managing Section
Joint Clinical Research Center
Joint Biobank
Business
Clinical Trial
Clinical Trial Agreement
Investigator-Initiated Trial
Project Writing Consultation
Ongoing Clinical Trials
Biobank
Biobank Application
Charges
TMU-JIRB
About TMU-JIRB
Introduction
Members
SOP
Application System
TMU-eJIRB System
IRB Account Controller Application
Application Process
Charges
Meeting Date
FAQs
Download
Forms
Clinical Trial
Regulation
TMU Regulation
Domestic Regulation
Related Regulation
Links
Online Portals
TMU Online Resources
External Online Resources
Affiliated Hospitals
REACTA 2024
Contact
Contact Info
Website Feedback Form
Home
Ongoing Clinical Trials
Ongoing Clinical Trials
Indication
All
overweight and obesity
Esophagus:process
Knee Osteoarthritis (KOA)
Pancreatic Cancer
Dermatosis/skin disease
Cell Therapy
Asthma
Solid tumors
Chronic obstructive pulmonary disease (COPD)
Rhinosinusitis
Lung Cancer
Endometriosis
Diabetes
Hepatitis B or D Infection
Hepatocellular Carcinoma (HCC)
Pregnant Women
Non-Alcoholic Fatty Liver
Healthy Volunteer
Systemic Lupus Erythematosus
Sjögren’s syndrome (NEPTUNUS-2)
Gout
COVID-20
Hemodialysis
Chronic Kidney Disease
Chronic Kidney Disease
heart failure
major adverse cardiovascular events
Coronary Syndrome
Spinal Cord Injuries (SCI)
High Blood Pressure/Hypertension
Hypercholesterolemia
Urinary Tract Infections
Influenza Vaccine
COVID-21
Breast Cancer
Cancer Patients
Interstitial lung disease
Femtosecond Ophthalmic
Chronic Kidney Disease (CKD)
Melanoma
Tibial fracture
COVID-19
Acute Respiratory Syncytial Virus Infection
Viral Lung Infection Requiring Supplemental Oxygen (TILIA)
Focal segmental glomerulosclerosis (FSGS)
Nephropathy
Diabetes and Chronic Kidney Disease
chronic obstructive pulmonary disease (COPD)
Chronic Plaque Psoriasis
Atopic Dermatitis
Myasthenia Gravis
Proliferative Lupus Nephritis
Knee Osteoarthritis (KOA)
Ulcerative Colitis (UC)
Atrial fibrillation
Ischemic stroke
Persistent Cancer Pain
Institution
All
TMUH
WFH
SHH
Department
All
Colorectal Surgery
Oral Surgery
Orthopedics
Radiation Oncology
Dermatology
Plastic Surgery
Pulmonary Medicine/Sleep Clinic
Pulmonary Medicine
Obstetrics
Endocrinology and Metabolism
Gastroenterology
Pediatrics
Rheumatology
Family Medicine
Nephrology
Cardiology
Urology
Hematology and Oncology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Internal Medicine/Neurology
Hematology And Oncology
Cardiovascular Surgery
Infection
Neurology
Allergy, Immunology and Rheumatology
Principal Investigator
All
Wei Wang
Chia-Yu Wu
Jia-Lin, Wu
Long-Sheng Lu
Lee,Tsung-Ju
Li-Wei Tang
Pai-Chien Chou
Chao-Hua Chiu
Timothy Chiu
Shuen-Fu Weng
Wei-Yu Kao
Heng-Kien Au
Chun-Chao Chang
Chia-Yau Chang
Chi-Ching Chang
Shy-Shin Chang
Cheng Tiong
Han-Pin Kuo
Hsi-Hsien, Chen
Chun-Yao Huang
MING-CHE LIU
Yen-Lin Liu
Jia-Ruey Tsai
Yung-Hsiao,Chiang
Shih-Hsin Hsiao
Chi-Li Chung
Le-Ming Wang
Chien-Liang Wu
Jia-Ying Sung
Tzeon-Jye Chiou
Chun-Che Shih
Chia-Lun Chang
Kuo Yi-Jie
Fu-Lun Chen
Tsong-Yih Ou
Ming-Hsiung Hsieh
Mai-Szu Wu
Kang-Yun Lee
Woan-Ruoh Lee
Hou-Chang Chiu
Yu-Sheng Chang
Yung-Ho Hsu
Chih-Hwa Chen
Ming-Yao Chen
Chen Kuan-Yuan
Tzu-Tao Chen
Lung Chan
Po-Hao Feng
Chia-Lun Chou
Tsu-Yi Chao
Wei-Hong Cheng
Yao-Yu Hsieh
Protocol Title
Search
Clear
TMU-JIRB No.
Protocol Title
Indication
Institution
Department
Principal Investigator
Contact
N202305080
ARTEMIS: Ravulizumab to Protect Patients with Chronic Kidney Disease (CKD) from Cardiac Surgery Associated Acute Kidney Injury (CSA AKI) and Subsequent Major Adverse Kidney Events (MAKE): A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study
Chronic Kidney Disease
WFH
Cardiovascular Surgery
Chun-Che Shih
Sih-Chen Wang
0958131385
N202005024
Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation
Lung Cancer
WFH
Hematology And Oncology
Chia-Lun Chang
Wei-Ling Yang
0229307930 #2556
N202301037
A Phase I, Open-label, Dose-escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Modified Salmonella Typhimurium SGN1 Administered via Intratumoral Injection in Patients with Advanced Solid Tumors
Solid tumors
WFH
Hematology And Oncology
Chia-Lun Chang
Wei-Ling Zhou
0914019869
N202306066
A Randomized, Double blind Study Evaluating Pharmacokinetic Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Resected Stage III or Stage IV Melanoma Subjects in the Adjuvant Setting
Melanoma
WFH
Hematology And Oncology
Chia-Lun Chang
Wei-Ling Zhou
0914019869
N202204010
A randomized, evaluator-blinded, controlled study to evaluate the safety and clinical performance of OIF/β-TCP in patients with open tibial fractures in need of bone grafting.
Tibial fracture
WFH
Orthopedics
Kuo Yi-Jie
Hsiu-Chen Chang
0229307930 #2550
N202107070
A Prospective, Randomized, Open-Label, Add-On, Parallel Control Study to Investigate Safety and Efficacy of the cold water extract of Arthrospira maxima in Patients with Ambulatory Mild and Moderated Disease COVID-19
COVID-19
WFH
Infection
Fu-Lun Chen
Hsiu-Yen Wang
0229307930 #2544
N202301029
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non-hospitalized Adults with Acute Respiratory Syncytial Virus Infection who are at High Risk for Complications
Acute Respiratory Syncytial Virus Infection
WFH
Infection
Tsong-Yih Ou
Hsiu-Chen Chang
0229307930 #2550
N202302038
A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA).
Viral Lung Infection Requiring Supplemental Oxygen (TILIA)
WFH
Infection
Tsong-Yih Ou
Hsiu-Chen Chang
0229307930 #2550
N202207016
A Multicentre, Randomized, Double-blind Study to Evaluate and Compare the Efficacy and Safety of 8-week Treatment with Azilsartan Medoxomil and Amlodipine Besylate Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects
High Blood Pressure/Hypertension
WFH
Cardiology
Ming-Hsiung Hsieh
Sih-Chen Wang
0958131385
N202203001
A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB)
Focal segmental glomerulosclerosis (FSGS)
SHH
Nephrology
Mai-Szu Wu
Ya-Chun Chang
0976909019
1
2
3
4
5
6
7
8
9
10
11
12
13
/
13
TOP